We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
Read MoreHide Full Article
In line with Hologic, Inc.’s (HOLX - Free Report) focus to grow within the promising space of GYN Surgical, it recently came up with a significant breakthrough. The company has made the U.S. launch of its Omni hysteroscope, an advanced three-in-one modular scope. Hologic claims this device to have advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures.
The company in this regard noted that a direct visualization of the uterine cavity in women with abnormal uterine bleeding is considered a gold standard. This allows accurate identification and collection of quality samples and remove pathology in a safer and more effective manner than traditional methods like blind biopsy and curettage.
Earlier this month, Omni hysteroscope received 510(k) clearance from the FDA. According to Hologic, the device is compatible with all MyoSure tissue removal offerings including MyoSure REACH, MyoSure XL, MyoSure LITE and MyoSure MANUAL devices.
Market Potential
Hologic’s strategy to gain traction from the GYN Surgical segment seems to be aligned with data provided by Prescient & Strategic (P&S) Intelligence. Per the report, the global hysteroscope market is expected to witness a CAGR of 4.5% between 2016 and 2022.
It is further believed that increasing female geriatric population, growing uterine cancer cases, rising female infertility incidences, increasing cases with abnormal uterine bleeding and rising customer needs of minimally invasive treatments will fuel growth for the global hysteroscope market. In view of these encouraging factors, we believe that the company’s development regarding the Fluent system is strategic and it is likely to broaden customer base.
GYN Surgical at a Glance
After a dull performance in the first half of fiscal 2018, the GYN Surgical business performed impressively during the fiscal fourth quarter. Although NovaSure sales declined, we are upbeat about the solid quarterly show by MyoSure. According to Hologic, the recent ordering patterns will continue to help GYN Surgical improve trends in the latter half of the current fiscal. New leadership, easier comparisons, revamped sales and marketing efforts are anticipated to drive growth. Per management, NovaSure sales have started to stabilize and also shown a decent progress on a sequential basis. However, Novasure sales declined in mid-single digit from the prior-year period.
Per Hologic, Myosure has gained a reputation of being the largest product line in the Surgical business. This product line has been consistently delivering a strong performance and saw low-double digits in the fiscal fourth quarter.
We are optimistic about the commercial launch of MyoSure MANUAL device in the United States. Notably, in addition to MyoSure MANUAL, the Myosure product portfolio consists of MyoSure, MyoSure REACH, MyoSure XL and MyoSure LITE devices.
Hologic recently unveiled the Fluent fluid management system in the United States during the fiscal fourth quarter. Management seems to pin hopes on the encouraging early interest of its customers in the product.
Going forward, Hologic predicts its surgical business to witness a solid uptick on steady expansion of MyoSure suite of products, stability in NovaSure and the growing international business.
Share Price Movement
Hologic has consistently outperformed its industry over the past three months. The stock has gained 8.5% versus 10.8% decline of the industry.
Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) Surmodics, Inc (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has a Zacks Rank #2 (Buy) and an earnings growth rate of 31.2% for the fourth quarter.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock holds a Zacks Rank of 2.
Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
In line with Hologic, Inc.’s (HOLX - Free Report) focus to grow within the promising space of GYN Surgical, it recently came up with a significant breakthrough. The company has made the U.S. launch of its Omni hysteroscope, an advanced three-in-one modular scope. Hologic claims this device to have advanced visualization capabilities designed for both diagnostic and therapeutic hysteroscopic procedures.
The company in this regard noted that a direct visualization of the uterine cavity in women with abnormal uterine bleeding is considered a gold standard. This allows accurate identification and collection of quality samples and remove pathology in a safer and more effective manner than traditional methods like blind biopsy and curettage.
Earlier this month, Omni hysteroscope received 510(k) clearance from the FDA. According to Hologic, the device is compatible with all MyoSure tissue removal offerings including MyoSure REACH, MyoSure XL, MyoSure LITE and MyoSure MANUAL devices.
Market Potential
Hologic’s strategy to gain traction from the GYN Surgical segment seems to be aligned with data provided by Prescient & Strategic (P&S) Intelligence. Per the report, the global hysteroscope market is expected to witness a CAGR of 4.5% between 2016 and 2022.
It is further believed that increasing female geriatric population, growing uterine cancer cases, rising female infertility incidences, increasing cases with abnormal uterine bleeding and rising customer needs of minimally invasive treatments will fuel growth for the global hysteroscope market. In view of these encouraging factors, we believe that the company’s development regarding the Fluent system is strategic and it is likely to broaden customer base.
GYN Surgical at a Glance
After a dull performance in the first half of fiscal 2018, the GYN Surgical business performed impressively during the fiscal fourth quarter. Although NovaSure sales declined, we are upbeat about the solid quarterly show by MyoSure. According to Hologic, the recent ordering patterns will continue to help GYN Surgical improve trends in the latter half of the current fiscal. New leadership, easier comparisons, revamped sales and marketing efforts are anticipated to drive growth. Per management, NovaSure sales have started to stabilize and also shown a decent progress on a sequential basis. However, Novasure sales declined in mid-single digit from the prior-year period.
Per Hologic, Myosure has gained a reputation of being the largest product line in the Surgical business. This product line has been consistently delivering a strong performance and saw low-double digits in the fiscal fourth quarter.
We are optimistic about the commercial launch of MyoSure MANUAL device in the United States. Notably, in addition to MyoSure MANUAL, the Myosure product portfolio consists of MyoSure, MyoSure REACH, MyoSure XL and MyoSure LITE devices.
Hologic recently unveiled the Fluent fluid management system in the United States during the fiscal fourth quarter. Management seems to pin hopes on the encouraging early interest of its customers in the product.
Going forward, Hologic predicts its surgical business to witness a solid uptick on steady expansion of MyoSure suite of products, stability in NovaSure and the growing international business.
Share Price Movement
Hologic has consistently outperformed its industry over the past three months. The stock has gained 8.5% versus 10.8% decline of the industry.
Zacks Rank & Key Picks
Hologic currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Integer Holdings Corporation (ITGR - Free Report) Surmodics, Inc (SRDX - Free Report) and Veeva Systems (VEEV - Free Report) .
Integer Holdings has a Zacks Rank #2 (Buy) and an earnings growth rate of 31.2% for the fourth quarter.
Surmodics’ long-term earnings growth rate is projected at 10%. The stock holds a Zacks Rank of 2.
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>